Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

NASDAQ:BDSX - Nasdaq - US09075X1081 - Common Stock - Currency: USD

0.713  -0.08 (-10.09%)

After market: 0.8798 +0.17 (+23.39%)

Fundamental Rating

3

Overall BDSX gets a fundamental rating of 3 out of 10. We evaluated BDSX against 108 industry peers in the Health Care Providers & Services industry. BDSX may be in some trouble as it scores bad on both profitability and health. BDSX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDSX had negative earnings in the past year.
In the past year BDSX has reported a negative cash flow from operations.
BDSX had negative earnings in each of the past 5 years.
In the past 5 years BDSX always reported negative operating cash flow.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

The Return On Assets of BDSX (-42.65%) is worse than 86.92% of its industry peers.
BDSX has a worse Return On Equity (-157.30%) than 83.18% of its industry peers.
Industry RankSector Rank
ROA -42.65%
ROE -157.3%
ROIC N/A
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

1.3 Margins

With an excellent Gross Margin value of 77.72%, BDSX belongs to the best of the industry, outperforming 91.59% of the companies in the same industry.
BDSX's Gross Margin has been stable in the last couple of years.
BDSX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BDSX has more shares outstanding
Compared to 5 years ago, BDSX has more shares outstanding
BDSX has a worse debt/assets ratio than last year.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.37, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX has a worse Altman-Z score (-5.37) than 86.92% of its industry peers.
BDSX has a Debt/Equity ratio of 1.30. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.30, BDSX is doing worse than 69.16% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.3
Debt/FCF N/A
Altman-Z -5.37
ROIC/WACCN/A
WACC9.67%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

BDSX has a Current Ratio of 3.40. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
BDSX has a Current ratio of 3.40. This is amongst the best in the industry. BDSX outperforms 87.85% of its industry peers.
A Quick Ratio of 3.40 indicates that BDSX has no problem at all paying its short term obligations.
BDSX has a better Quick ratio (3.40) than 87.85% of its industry peers.
Industry RankSector Rank
Current Ratio 3.4
Quick Ratio 3.4
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

BDSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.67%, which is quite impressive.
The Revenue has grown by 48.90% in the past year. This is a very strong growth!
Measured over the past years, BDSX shows a quite strong growth in Revenue. The Revenue has been growing by 19.16% on average per year.
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)48.9%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Sales Q2Q%34.54%

3.2 Future

The Earnings Per Share is expected to grow by 20.72% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 32.04% on average over the next years. This is a very strong growth
EPS Next Y45.34%
EPS Next 2Y28.84%
EPS Next 3Y20.72%
EPS Next 5YN/A
Revenue Next Year41.14%
Revenue Next 2Y36.31%
Revenue Next 3Y32.04%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

BDSX's earnings are expected to grow with 20.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.84%
EPS Next 3Y20.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDSX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (3/3/2025, 8:14:22 PM)

After market: 0.8798 +0.17 (+23.39%)

0.713

-0.08 (-10.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-01 2024-11-01/bmo
Earnings (Next)03-03 2025-03-03/amc
Inst Owners35.83%
Inst Owner Change-3.17%
Ins Owners26.2%
Ins Owner Change5.67%
Market Cap103.72M
Analysts83.33
Price Target3.16 (343.2%)
Short Float %1.11%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.58%
Min EPS beat(2)6.41%
Max EPS beat(2)14.75%
EPS beat(4)4
Avg EPS beat(4)9.07%
Min EPS beat(4)4.24%
Max EPS beat(4)14.75%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)9
Avg EPS beat(12)2.95%
EPS beat(16)11
Avg EPS beat(16)1.65%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-4.39%
Max Revenue beat(2)8.39%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-7.86%
Max Revenue beat(4)8.39%
Revenue beat(8)3
Avg Revenue beat(8)-2.53%
Revenue beat(12)5
Avg Revenue beat(12)0.16%
Revenue beat(16)8
Avg Revenue beat(16)2.5%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.58
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 16.24
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.45
BVpS0.19
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.65%
ROE -157.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-59.93%
ROA(5y)-55.91%
ROE(3y)-558.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.43%
GM growth 5Y-1.3%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 1.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.83%
Cap/Sales 8.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.4
Quick Ratio 3.4
Altman-Z -5.37
F-Score4
WACC9.67%
ROIC/WACCN/A
Cap/Depr(3y)290.4%
Cap/Depr(5y)199.46%
Cap/Sales(3y)20.3%
Cap/Sales(5y)14.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y45.34%
EPS Next 2Y28.84%
EPS Next 3Y20.72%
EPS Next 5YN/A
Revenue 1Y (TTM)48.9%
Revenue growth 3Y2.52%
Revenue growth 5Y19.16%
Sales Q2Q%34.54%
Revenue Next Year41.14%
Revenue Next 2Y36.31%
Revenue Next 3Y32.04%
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.01%
EBIT Next 3Y25.74%
EBIT Next 5YN/A
FCF growth 1Y-37.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.53%
OCF growth 3YN/A
OCF growth 5YN/A